ACELYRIN Inc

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Acelyrin Inc reports strong Q2 results, optimistic on transformative medicines

Acelyrin Inc showcased positive trial data for izokibep in HS and PsA, emphasizing transformative medicines
Company's strong financial position post-IPO and detailed responses on key program benefits
Analyst questions highlighted focus on trial timelines, differentiation, and dosing strategies
Overall positive outlook on pipeline and commitment to delivering innovative medicines

Acelyrin reports strong Q2 results, focuses on lonigutamab progress

Acelyrin Inc (SLRN) showcased positive performance in key drug programs and financial sustainability measures during Q2 2024.
While facing challenges such as workforce reductions and tinnitus cases, the company remains well-positioned for growth and clinical advancement.
Opportunities lie in engaging with regulators, sharing program updates, and leveraging their cash position for strategic expansion.
Investors can expect continued progress and transparency from Acelyrin as they navigate clinical milestones and investor engagements.

Acelyrin Inc advances lonigutamab towards Phase III, bolstered by financial strength

Acelyrin Inc's Q3 performance highlights progress in clinical development, financial stability, and strategic planning for future growth.
While facing challenges in dose announcements and study design details, the company's strengths in FDA alignment, financial flexibility, and proactive engagement present opportunities for expansion and success.
Overall, Acelyrin's positive momentum in product development and regulatory milestones positions them favorably for continued advancement and potential market impact.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.

LOS ANGELES, CA / ACCESSWIRE / September 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Acelyrin, Inc. ("Acelyrin" or "the Company") (NASDAQ:SLRN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Acelyrin, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Acelyrin, Inc. ("Acelyrin" or "the Company") (NASDAQ:SLRN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acelyrin, Inc. and Encourages Investors with Losses to Contact the Firm

Acelyrin's izokibep failed to meet statistical significance in its primary endpoint in a clinical trial evaluating the drug for the treatment of a skin inflammatory disorder. Shares of the biopharma company fell more than 50%, wiping out all of its post-IPO gains.

Why Acelyrin Stock Plummeted 59% This Week

LOS ANGELES, CA / ACCESSWIRE / September 14, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Acelyrin, Inc. ("Acelyrin" or "the Company") (NASDAQ:SLRN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acelyrin, Inc. and Encourages Investors with Losses to Contact the Firm

ACELYRIN (SLRN) fails to achieve statistically significant primary endpoint result in the hidradenitis suppurativa study of its lead candidate, izokibep. The stock of the company falls 54%.

ACELYRIN (SLRN) Fails to Meet Goal in HS Study, Stock Down 54%

LOS ANGELES, CA / ACCESSWIRE / September 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Acelyrin, Inc. ("Acelyrin" or "the Company") (NASDAQ:SLRN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acelyrin, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 12, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Acelyrin, Inc. ("Acelyrin" or "the Company") (NASDAQ:SLRN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Acelyrin, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

MoonLake Immunotherapeutics

MoonLake shares rocketed Tuesday after rival Acelyrin reported a failure for its skin disease treatment. MLTX stock neared a record.

The Surprising Acelyrin News That Sent Rival MoonLake, A Top 1% Stock, Soaring 13%

Publicly traded since May, Acelyrin Inc (NASDAQ:SLRN) stock is plummeting to record lows today.

Pharma Stock Plummets on Skin Disease Trial

Acelyrin Inc (NASDAQ:SLRN) collapsed, down some 58% ahead of Tuesday's open, after the company revealed the failure of its clinical trial which attempted to reduce symptoms of inflammatory skin disease. The stock traded at its lowest point in its short history, following its May 2023 IPO which raised $540 million from investors who were effectively betting on the success of trials like this.

Acelyrin stock collapses after skin drug trail failure

Acelyrin (NASDAQ: SLRN ) stock is falling hard on Tuesday after the biopharma company announced clinical trial results. That bad news for investors in SLRN stock comes from the company's Part B of a Phase 2b/3 trial evaluating izokibep.

Why Is Acelyrin (SLRN) Stock Down 58% Today?

Shares of drug developer Acelyrin slumped 57% in premarket trading on Tuesday after the company's experimental lead drug failed to show it was effective enough in reducing symptoms of an inflammatory skin disease.

Acelyrin tumbles after skin disease drug fails key trial

The primary endpoint of HiSCR75 at week 16 did not meet statistical significance in the Non-Responder Imputation (NRI) primary analysis.

ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa

LOS ANGELES, Sept. 06, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that Founder and Chief Executive Officer Shao-Lee Lin, MD, PhD will participate in a moderated fireside chat during the Morgan Stanley 21st Annual Global Healthcare Conference being held September 11-13, 2023 in New York.

ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

NEXTracker Inc

Skyward Specialty Insurance Group Inc

Initial public offering (IPO) is the stock issuance process onto the public market. There are a few different methods by which a company will first become listed on a stock exchange.

3 Up-and-Coming IPOs to Put on Your Must-Buy List

Acelyrin, Inc. (NASDAQ:SLRN ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Tyler Marciniak - VP of Investor Relations, Communications, and Corporate Operations Shao-Lee Lin - Founder and Chief Executive Officer Paul Peloso - Chief Medical Officer Gil Labrucherie - Interim Chief Financial Officer Conference Call Participants Tyler Van Buren - TD Cowen Akash Tewari - Jefferies Vikram Purohit - Morgan Stanley Operator Good afternoon and welcome to the ACELYRIN, INC. Conference Call to discuss its Financial Results for the Second Quarter 2023 and Other Corporate Updates.

Acelyrin, Inc. (SLRN) Q2 2023 Earnings Call Transcript

New data from Part A of Phase 2b/3 trial of izokibep in Hidradenitis Suppurativa demonstrated improvements in number of draining tunnels in two-thirds of patients as early as week 4; the placebo-controlled Part B remains on track for top-line data in the third quarter 2023.

ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights

LOS ANGELES, Aug. 07, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Monday, August 14, 2023 at 4:30 p.m. ET to discuss its second quarter 2023 financial results and provide a corporate update.

ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023

American Assets

Akoya Biosciences Inc

American Vanguard

Cannae Hlds

Domo

Enviva Partners

National Vision Hlds

Globalstar

Heartland Express

I3 Verticals

MillerKnoll

PacWest Bancorp

Pebblebrook Hotel Trust

Pulse Biosciences

B. Riley Financial

Skillz

SPDR S&P 500 ETF Trust

Stellar Bancorp Inc

StepStone Group

Washington Federal

Zumiez

After covering second-quarter corporate insider activity among mid-cap and large-caps, today's article will cover on the most interesting insider purchases for small-cap companies. Corporate insiders at American Assets Trust, National Vision, Skillz, Enviva, Heartland Express, and Zumiez have been buying significant amounts of shares, signaling confidence in their respective companies. Other notable insider activity among small-cap stocks includes B. Riley Financial, Cannae Holdings, i3 Verticals, whose CEOs have bought million worth of stock in the second quarter.

Strong Small-Cap Insider Buys: Q2 2023

Accomplished global leader brings 20 years of immunology sales and marketing expertise. ACEYLRIN currently has a robust portfolio including late-stage clinical trials underway supporting multiple potential commercial launches in coming years.

ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer

Cava Group, Inc.

Restaurant Brands

Many investors know that 2021 was a record year for initial public offerings (IPOs) in the United States. Of course, last year brought a near-complete halt to this space, with many must-watch stocks slated for IPOs putting off their plans, waiting for higher prices to materialize.

3 Must-Watch Stocks as IPO Valuations Skyrocket

Atmus Filtration Technologies Inc

Renaissance IPO ETF

The IPO market is expected to thrive in the second half of 2023. Deals are getting larger and less volatile.

The IPO Market Picks Up. These Companies Are Set To Go Public.

Initial Public Offering generated gross proceeds of $621 million; net proceeds of $573.7 million–  Strong cash position of $289.2 million at end of Q1 2023–  $862.9 million from IPO net proceeds and existing cash balance on March 31, 2023 expected to fund key milestones across all three clinical programs

ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights

LOS ANGELES , May 9, 2023 /PRNewswire/ -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the closing of its previously announced upsized initial public offering of 34,500,000 shares of common stock, including the full exercise of the underwriters' option to purchase up to 4,500,000 additional shares, at a price to the public of $18.00 per share.

ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Acelyrin shares have added about 30% after the late-stage clinical biopharma raised $540 million during an upsized initial public offering (IPO). This was the fifth-largest US IPO by a traditional biopharma company in history, according to BioWorld.

News for ACELYRIN Inc Stock (SLRN)